Market Overview

The Panitumumab market is predicted to develop at a compound annual growth rate (CAGR) of xx from 2024 to 2034, when it is projected to reach USD xx Billion, based on an average growth pattern. The market is estimated to reach a value of USD xx Billion in 2024.

SOURCE: We Market Research

A monoclonal antibody called panitumumab targets the epidermal growth factor receptor (EGFR) and is used to treat metastatic colorectal cancer, particularly in patients with tumors that are KRAS wild-type. When given intravenously, it prevents the development of cancer cells by obstructing EGFR signaling pathways. Skin rash and low magnesium levels are common side effects; severe allergic reactions and lung problems are examples of major ones. Before starting treatment, KRAS mutation testing is necessary to guarantee efficacy. Panitumumab is sold under the Vectibix brand and is frequently used with other chemotherapeutic drugs.

The rise in colorectal cancer cases worldwide, technological developments, and the growing inclination towards targeted therapies over conventional chemotherapy because of their greater effectiveness and reduced side effects are the main factors propelling the panitumumab market. The need for treatments based on genetic profiles is increased by the emphasis on customized medicine. The need for panitumumab is further increased by an aging population that is more susceptible to cancer. The market's reach is increased by regulatory approvals for novel indications and combination medicines, and the overall expansion of the market is bolstered by better access to cutting-edge cancer treatments in emerging economies thanks to improved healthcare infrastructure.

Market Scope

 Panitumumab Industry: Dynamics & Restrains

Market opportunity:

We Market Research: Panitumumab Dashboard

Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.

Panitumumab Segmentation

Market- By Therapeutic Applications Analysis

By Therapeutic Applications, the Panitumumab Market is Categories into Colorectal Cancer, Others. The Colorectal Cancer segment accounts for the largest share of around 92% in 2024.

The primary driver for Panitumumab in colorectal cancer treatment is the increasing global incidence of colorectal cancer, coupled with the drug's effectiveness as a targeted therapy, improving patient outcomes and survival rates by inhibiting cancer cell growth and proliferation.

The following segments are part of an in-depth analysis of the global Panitumumab market:

Panitumumab Industry: Regional Analysis

North America Market Forecast

North America dominates the Panitumumab Market with the highest revenue generating market with share of more than 48%. The high incidence of colorectal cancer and advanced healthcare infrastructure are primary drivers of Panitumumab market growth. Additionally, substantial healthcare expenditure and the presence of major pharmaceutical companies foster a supportive environment for the adoption of targeted therapies, improving patient outcomes and expanding market potential.

Europe Market Statistics

In Europe, increasing prevalence of colorectal cancer and robust government support for cancer research and treatment drive the Panitumumab market. Access to advanced treatment options and well-established healthcare systems enhance the adoption of targeted therapies, contributing to market growth and improved patient care.

Asia Pacific Market Forecasts

Asia Pacific is expected to be the fastest-growing regional segment of the Panitumumab market during the forecast period. The Asia-Pacific region shows significant market potential due to rapidly rising cancer incidence and improving healthcare infrastructure significantly boost Panitumumab demand. Expanding healthcare access in emerging economies, coupled with increasing awareness and adoption of advanced cancer treatments, drive market growth, making the region a key focus for pharmaceutical companies.

Key Market Players

• Amgen  

1.      Global Panitumumab Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global Panitumumab Market Scope and Market Estimation

1.2.1. Global Panitumumab Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)

1.2.2. Global Panitumumab Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034

1.3.    Market Segmentation

1.3.1. Therapeutic Applications of Global Panitumumab Market

1.3.2. Dosage Forms of Global Panitumumab Market

1.3.3. Distribution Channels of Global Panitumumab Market

1.3.4. Region of Global Panitumumab Market

2.      Executive Summary

2.1.    Market Dynamics

2.1.1. Drivers

2.1.2. Limitations

2.1.3. Opportunities

2.1.4. Impact Analysis of Drivers and Restraints

2.2.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.3.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.4.    Porter’s Five Forces Analysis

2.4.1. Bargaining Power of Suppliers

2.4.2. Bargaining Power of Buyers

2.4.3. Threat of Substitutes

2.4.4. Threat of New Entrants

2.4.5. Competitive Rivalry

2.5.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global Panitumumab Market Estimates & Historical Trend Analysis (2019 - 2023)

4.      Global Panitumumab Market Estimates & Forecast Trend Analysis, by Therapeutic Applications

4.1.    Global Panitumumab Market Revenue (US$ Mn) Estimates and Forecasts, by Therapeutic Applications, 2019 to 2034

4.1.1. Colorectal Cancer

4.1.2. Others

5.      Global Panitumumab Market Estimates & Forecast Trend Analysis, by Dosage Forms

5.1.    Global Panitumumab Market Revenue (US$ Mn) Estimates and Forecasts, by Dosage Forms, 2019 to 2034

5.1.1. Injectable

5.1.2. Others

6.      Global Panitumumab Market Estimates & Forecast Trend Analysis, by Distribution Channels

6.1.    Global Panitumumab Market Revenue (US$ Mn) Estimates and Forecasts, by Distribution Channels, 2019 to 2034

6.1.1. Hospitals

6.1.2. Specialty Clinics

6.1.3. Pharmacies

6.1.4. Others

7.      Global Panitumumab Market Estimates & Forecast Trend Analysis, by region

7.1.    Global Panitumumab Market Revenue (US$ Mn) Estimates and Forecasts, by region, 2019 to 2034

7.1.1. North America

7.1.2. Europe

7.1.3. Asia Pacific

7.1.4. Middle East & Africa

7.1.5. South America

8.      North America Panitumumab Market: Estimates & Forecast Trend Analysis

8.1.    North America Panitumumab Market Assessments & Key Findings

8.1.1. North America Panitumumab Market Introduction

8.1.2. North America Panitumumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

8.1.2.1.   By Therapeutic Applications

8.1.2.2.   By Dosage Forms

8.1.2.3.   By Distribution Channels

8.1.2.4.   By Country

8.1.2.4.1.     The U.S.

8.1.2.4.2.     Canada

8.1.2.4.3.     Mexico

9.      Europe Panitumumab Market: Estimates & Forecast Trend Analysis

9.1.    Europe Panitumumab Market Assessments & Key Findings

9.1.1. Europe Panitumumab Market Introduction

9.1.2. Europe Panitumumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

9.1.2.1.   By Therapeutic Applications

9.1.2.2.   By Dosage Forms

9.1.2.3.   By Distribution Channels

9.1.2.4.        By Country

9.1.2.4.1.     Germany

9.1.2.4.2.     U.K.

9.1.2.4.3.     France

9.1.2.4.4.     Italy

9.1.2.4.5.     Spain

9.1.2.4.6.     Russia

9.1.2.4.7.     Rest of Europe

10.  Asia Pacific Panitumumab Market: Estimates & Forecast Trend Analysis

10.1.  Asia Pacific Market Assessments & Key Findings

10.1.1.   Asia Pacific Panitumumab Market Introduction

10.1.2.   Asia Pacific Panitumumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

10.1.2.1.    By Therapeutic Applications

10.1.2.2.    By Dosage Forms

10.1.2.3.    By Distribution Channels

10.1.2.4.    By Country

10.1.2.4.1. China

10.1.2.4.2. Japan

10.1.2.4.3. India

10.1.2.4.4. Australia

10.1.2.4.5. South Korea

10.1.2.4.6. ASEAN

10.1.2.4.7. Rest of Asia Pacific

11.  Middle East & Africa Panitumumab Market: Estimates & Forecast Trend Analysis

11.1.  Middle East & Africa Market Assessments & Key Findings

11.1.1.   Middle East & Africa Panitumumab Market Introduction

11.1.2.   Middle East & Africa Panitumumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

11.1.2.1.    By Therapeutic Applications

11.1.2.2.    By Dosage Forms

11.1.2.3.    By Distribution Channels

11.1.2.4.    By Country

11.1.2.4.1. U.A.E.

11.1.2.4.2. Saudi Arabia

11.1.2.4.3. Egypt

11.1.2.4.4. South Africa

11.1.2.4.5. Rest of Middle East & Africa

12.  South America Panitumumab Market: Estimates & Forecast Trend Analysis

12.1.  South America Market Assessments & Key Findings

12.1.1.   South America Panitumumab Market Introduction

12.1.2.   South America Panitumumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

12.1.2.1.    By Therapeutic Applications

12.1.2.2.    By Dosage Forms

12.1.2.3.    By Distribution Channels

12.1.2.4.    By Country

12.1.2.4.1. Brazil

12.1.2.4.2. Argentina

12.1.2.4.3. Colombia

12.1.2.4.4. Rest of South America

13.  Competition Landscape

13.1.  Global Panitumumab Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

13.2.  Global Panitumumab Market Competition White Space Analysis, By End-user

13.3.  Global Panitumumab Market Competition Heat Map Analysis, By End-user

13.4.  Global Panitumumab Market Concentration & Company Market Shares (%) Analysis, 2022

14.  Company Profiles

14.1.                     Amgen.

14.1.1.   Company Overview & Key Stats

14.1.2.   Financial Performance & KPIs

14.1.3.   Product Portfolio

14.1.4.   Business Strategy & Recent Developments

15.  Research Methodology

15.1.  External Transportations / Databases

15.2.  Internal Proprietary Database

15.3.  Primary Research

15.4.  Secondary Research

15.5.  Assumptions

15.6.  Limitations

15.7.  Report FAQs

16.  Research Findings & Conclusion